Celyad Oncology SA
XBRU:CYAD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.2295
1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Celyad Oncology SA
Celyad Oncology SA
Total Receivables
Celyad Oncology SA
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Celyad Oncology SA
XBRU:CYAD
|
Total Receivables
€2.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
M
|
MDxHealth SA
NASDAQ:MDXH
|
Total Receivables
$13.5m
|
CAGR 3-Years
46%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
12%
|
|
|
Galapagos NV
AEX:GLPG
|
Total Receivables
€101.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Oxurion NV
XBRU:OXUR
|
Total Receivables
€3.2m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Celyad Oncology SA
Glance View
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
See Also
What is Celyad Oncology SA's Total Receivables?
Total Receivables
2.8m
EUR
Based on the financial report for Jun 30, 2024, Celyad Oncology SA's Total Receivables amounts to 2.8m EUR.
What is Celyad Oncology SA's Total Receivables growth rate?
Total Receivables CAGR 5Y
48%
Over the last year, the Total Receivables growth was 33%. The average annual Total Receivables growth rates for Celyad Oncology SA have been -4% over the past three years , 48% over the past five years .
You don't have any saved screeners yet
